Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...
Carnival’s leading market share in the cruise industry sets it up to benefit the most from forecasted industry growth. See ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback